Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 52-week low of $0.01 and a 52-week high of $1.99. The company has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.